| Year |
Title |
Altmetric |
| 2022
|
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
2022
|
|
| 2022
|
John Q. Trojanowski, MD, PhD (1946-2022).
Movement Disorders.
37:1123-1124.
2022
|
|
| 2022
|
Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method.
Diagnostics.
12.
2022
|
|
| 2022
|
Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia.
Neurobiology of Disease.
166.
2022
|
|
| 2022
|
Alpha-synuclein-mediated DNA damage, STING activation, and neuroinflammation in Parkinson's disease
2022
|
|
| 2022
|
RORγt-Expressing Pathogenic CD4+ T Cells Cause Brain Inflammation during Chronic Colitis.
Journal of Immunology.
208:2054-2066.
2022
|
|
| 2022
|
Unaltered T cell responses to common antigens in individuals with Parkinson’s disease
2022
|
|
| 2022
|
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Journal of Parkinson's Disease.
12:917-926.
2022
|
|
| 2021
|
Exploring human-genome gut-microbiome interaction in Parkinson’s disease.
npj Parkinson's Disease.
7.
2021
|
|
| 2021
|
Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease.
npj Parkinson's Disease.
7.
2021
|
|
| 2021
|
The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse.
Scientific Reports.
11.
2021
|
|
| 2021
|
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.
npj Parkinson's Disease.
7.
2021
|
|
| 2021
|
Frameless MLC-Based Radiosurgical Thalamotomies on the Modern Linear Accelerator Platform - Prospective Phase I/II Clinical Trial Results
2021
|
|
| 2021
|
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.
Clinical Pharmacology and Therapeutics.
110:1368-1380.
2021
|
|
| 2021
|
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications.
Parkinsonism and Related Disorders.
92:59-66.
2021
|
|
| 2021
|
DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.
Movement Disorders Clinical Practice.
8:1061-1074.
2021
|
|
| 2021
|
CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease
2021
|
|
| 2021
|
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease.
Neurology, Neuroimmunology and Neuroinflammation.
8.
2021
|
|
| 2021
|
Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis.
Parkinsonism and Related Disorders.
86:52-57.
2021
|
|
| 2021
|
Gene-Environment Interactions in Progressive Supranuclear Palsy.
Frontiers in Neurology.
12.
2021
|
|
| 2021
|
Templated α-synuclein inclusion formation is independent of endogenous tau.
eNeuro.
8.
2021
|
|
| 2021
|
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.
Movement Disorders.
36:16-24.
2021
|
|
| 2020
|
Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.
npj Parkinson's Disease.
6.
2020
|
|
| 2020
|
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease.
Nature Communications.
11.
2020
|
|
| 2020
|
Brain Alchemy: Transforming Astrocytes into Neurons for Neurodegenerative Disease.
Movement Disorders Clinical Practice.
7:902-903.
2020
|
|
| 2020
|
Application of the †5-2-1' screening criteria in advanced Parkinson's disease: Interim analysis of DUOGLOBE.
Neurodegenerative Disease Management.
10:309-323.
2020
|
|
| 2020
|
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients.
Annals of Clinical and Translational Neurology.
7:1816-1830.
2020
|
|
| 2020
|
Understanding the relationship between freezing of gait and other progressive supranuclear palsy features.
Parkinsonism and Related Disorders.
78:56-60.
2020
|
|
| 2020
|
Progressive Supranuclear Palsy and Statin Use.
Movement Disorders.
35:1253-1257.
2020
|
|
| 2020
|
Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens..
npj Parkinson's Disease.
6:11.
2020
|
|
| 2020
|
Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
Movement Disorders.
35:1055-1061.
2020
|
|
| 2020
|
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease.
Acta Neuropathologica.
139:855-874.
2020
|
|
| 2020
|
Defining research priorities in dystonia.
Neurology.
94:526-537.
2020
|
|
| 2020
|
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.
Neurology.
94:481-494.
2020
|
|
| 2020
|
Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Neurobiology of Disease.
134.
2020
|
|
| 2020
|
Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.
Movement Disorders.
35:231-234.
2020
|
|
| 2020
|
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Lancet Neurology.
19:71-80.
2020
|
|
| 2020
|
Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed in Person.
Journal of Parkinson's Disease.
10:677-691.
2020
|
|
| 2020
|
Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience.
Journal of Parkinson's Disease.
10:665-675.
2020
|
|
| 2019
|
Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?.
Parkinsonism and Related Disorders.
69:34-39.
2019
|
|
| 2019
|
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?.
Neurobiology of Disease.
132.
2019
|
|
| 2019
|
Child Neurology: Spastic paraparesis and dystonia with a novel ADCY5 mutation.
Neurology.
93:510-514.
2019
|
|
| 2019
|
Diverse mechanisms lead to common dysfunction of striatal cholinergic interneurons in distinct genetic mouse models of Dystonia
2019
|
|
| 2019
|
Hypertension and progressive supranuclear palsy.
Parkinsonism and Related Disorders.
66:166-170.
2019
|
|
| 2019
|
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
Parkinsonism and Related Disorders.
62:201-209.
2019
|
|
| 2019
|
Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats.
Movement Disorders Clinical Practice.
6:336-337.
2019
|
|
| 2019
|
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
Neurology.
92:329-337.
2019
|
|
| 2019
|
Widespread tau-specific CD4 T cell reactivity in the general population.
Journal of Immunology.
203:84-92.
2019
|
|
| 2018
|
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.
npj Parkinson's Disease.
4.
2018
|
|
| 2018
|
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Epilepsy and Behavior.
87:131-136.
2018
|
|
| 2018
|
Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Journal of Neuroinflammation.
15.
2018
|
|
| 2018
|
Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners.
Movement Disorders Clinical Practice.
5:383-393.
2018
|
|
| 2018
|
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Movement Disorders.
33:928-936.
2018
|
|
| 2018
|
Anti-inflammatory drug use and progressive supranuclear palsy.
Parkinsonism and Related Disorders.
48:89-92.
2018
|
|
| 2018
|
Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.
Movement Disorders.
33:468-472.
2018
|
|
| 2018
|
Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.
Experimental Neurology.
300:179-187.
2018
|
|
| 2018
|
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
Pongkiat Kankirawatana, Dr Rani Singh, Professor David G Standaert, Dr Yuliang Liu, Dr Leon Dure, Dr Jennifer DeWollfe, Professor Gary Cutter, Dr Tyler Gaston, Dr Ashley Thomas, Professor E. Martina Bebin, Dr. Lawrence Ver Hoef.
Epilepsy and Behavior.
(in press).
2018
|
|
| 2017
|
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial.
npj Parkinson's Disease.
3.
2017
|
|
| 2017
|
Genetic influences on cognition in progressive supranuclear palsy.
Movement Disorders.
32:1764-1771.
2017
|
|
| 2017
|
Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.
Movement Disorders Clinical Practice.
4:829-837.
2017
|
|
| 2017
|
What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
Movement Disorders.
32:1341-1342.
2017
|
|
| 2017
|
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
Movement Disorders.
32:1264-1310.
2017
|
|
| 2017
|
Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia.
Experimental Neurology.
295:162-175.
2017
|
|
| 2017
|
Evaluation of AZD1446 as a therapeutic in DYT1 dystonia.
Frontiers in Systems Neuroscience.
11.
2017
|
|
| 2017
|
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Neurobiology of Disease.
102:125-132.
2017
|
|
| 2017
|
The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.
Brain Stimulation.
10:651-656.
2017
|
|
| 2017
|
An individualized coaching program for patients with acute ischemic stroke: Feasibility study.
Clinical Neurology and Neurosurgery.
154:89-93.
2017
|
|
| 2017
|
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
Movement Disorders.
32:319-324.
2017
|
|
| 2017
|
Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications.
European Polymer Journal.
88:524-552.
2017
|
|
| 2017
|
Effects of Subthalamic Nucleus Deep Brain Stimulation on Objective Sleep Outcomes in Parkinson's Disease.
Movement Disorders Clinical Practice.
4:183-190.
2017
|
|
| 2017
|
Understanding falls in progressive supranuclear palsy.
Parkinsonism and Related Disorders.
35:75-81.
2017
|
|
| 2017
|
The role of stress as a risk factor for progressive supranuclear palsy.
Journal of Parkinson's Disease.
7:377-383.
2017
|
|
| 2016
|
Cholinergic regulation of striatal dopamine release: New light in dark basements.
Movement Disorders.
31:1796.
2016
|
|
| 2016
|
Glucocerebrosidase, Parkinson disease, and the “senses and intellect”.
Annals of Neurology.
80:660-661.
2016
|
|
| 2016
|
How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?.
Journal of Neurochemistry.
131-155.
2016
|
|
| 2016
|
SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.
Movement Disorders.
31:1479.
2016
|
|
| 2016
|
Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.
Movement Disorders.
31:1543-1550.
2016
|
|
| 2016
|
Dynamic DNA methylation regulates levodopa-induced Dyskinesia
2016
|
|
| 2016
|
Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.
Movement Disorders.
31:769-770.
2016
|
|
| 2016
|
The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia.
Journal of Neuroimmune Pharmacology.
11:231-237.
2016
|
|
| 2016
|
Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration
2016
|
|
| 2016
|
Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.
Movement Disorders.
31:644-652.
2016
|
|
| 2016
|
MicroRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease
2016
|
|
| 2016
|
Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis.
Movement Disorders Clinical Practice.
3:65-67.
2016
|
|
| 2016
|
CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial.
Neurology, Neuroimmunology and Neuroinflammation.
3.
2016
|
|
| 2016
|
Invisible Killers.
Movement Disorders.
31:44-44.
2016
|
|
| 2015
|
ID: 163.
Cytokine.
76:64-64.
2015
|
|
| 2015
|
Fractalkine signaling regulates the inflammatory response in an α-synuclein model of Parkinson disease.
PLoS ONE.
10.
2015
|
|
| 2015
|
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.
Movement Disorders.
30:1371-1381.
2015
|
|
| 2015
|
Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
Movement Disorders.
30:1435-1436.
2015
|
|
| 2015
|
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
Movement Disorders.
30:919-927.
2015
|
|
| 2015
|
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results.
Movement Disorders.
30:500-509.
2015
|
|
| 2015
|
Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia.
Progress in Neurobiology.
127-128:91-107.
2015
|
|
| 2015
|
A Full-Brain, Bootstrapped Analysis of Diffusion Tensor Imaging Robustly Differentiates Parkinson Disease from Healthy Controls.
Neuroinformatics.
13:7-18.
2015
|
|
| 2015
|
Direct measurement of the Hypercholinergic state in a mouse model of DYT1 Dystonia.
Frontiers in Neurology.
6.
2015
|
|
| 2015
|
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.
Journal of Parkinson's Disease.
5:1-19.
2015
|
|
| 2014
|
Monocytes and Parkinson's disease: Invaders from outside?.
Movement Disorders.
29:1242.
2014
|
|
| 2014
|
Scientific perspectives.
Movement Disorders.
29:1230.
2014
|
|
| 2014
|
Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.
Viruses.
6:3293-3310.
2014
|
|
| 2014
|
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.
Journal of Comparative Neurology.
522:2465-2480.
2014
|
|
| 2014
|
Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease
2014
|
|
| 2014
|
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: A randomised, controlled, double-blind, double-dummy study.
Lancet Neurology.
13:141-149.
2014
|
|
| 2014
|
Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration.
Movement Disorders.
29:306-306.
2014
|
|
| 2013
|
LRRK2 secretion in exosomes is regulated by 14-3-3.
Human Molecular Genetics.
22:4988-5000.
2013
|
|
| 2013
|
Metabolomics and the search for biomarkers in Parkinson's disease.
Movement Disorders.
28:1620-1621.
2013
|
|
| 2013
|
Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
Movement Disorders.
28:1675-1682.
2013
|
|
| 2013
|
MHCII is required for α-Synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration
2013
|
|
| 2013
|
Removing the blinkers: Moving beyond striatal dopamine in Parkinson's disease.
Journal of Neurochemistry.
125:639-641.
2013
|
|
| 2013
|
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results.
Parkinsonism and Related Disorders.
19:339-345.
2013
|
|
| 2013
|
Angiogenin in Parkinson Disease Models: Role of Akt Phosphorylation and Evaluation of AAV-Mediated Angiogenin Expression in MPTP Treated Mice.
PLoS ONE.
8.
2013
|
|
| 2012
|
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease.
Journal of Neuroimmune Pharmacology.
7:927-938.
2012
|
|
| 2012
|
The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia.
Journal of Neuroinflammation.
9.
2012
|
|
| 2012
|
Evaluation of TorsinA as a Target for Parkinson Disease Therapy in Mouse Models.
PLoS ONE.
7.
2012
|
|
| 2012
|
Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA.
Neurobiology of Disease.
47:416-427.
2012
|
|
| 2012
|
Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia
2012
|
|
| 2012
|
Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia.
PLoS ONE.
7.
2012
|
|
| 2012
|
LRRK2 inhibition attenuates microglial inflammatory responses
2012
|
|
| 2012
|
Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease.
Parkinsonism and Related Disorders.
18:63-68.
2012
|
|
| 2011
|
The Parkinson Progression Marker Initiative (PPMI).
Progress in Neurobiology.
95:629-635.
2011
|
|
| 2011
|
Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout mice.
PLoS ONE.
6.
2011
|
|
| 2011
|
Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia.
PLoS ONE.
6.
2011
|
|
| 2011
|
Update on the pathology of dystonia.
Neurobiology of Disease.
42:148-151.
2011
|
|
| 2011
|
Altered dendritic morphology of Purkinje cells in DYT1 δGAG knock-in and Purkinje cell-specific DYT1 conditional knockout mice.
PLoS ONE.
6.
2011
|
|
| 2011
|
A neuroprotective role for angiogenin in models of Parkinson's disease.
Journal of Neurochemistry.
116:334-341.
2011
|
|
| 2011
|
Parkinson's disease, primates, and gene therapy: Vive la différence?.
Movement Disorders.
26:2-3.
2011
|
|
| 2010
|
Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
PLoS ONE.
5.
2010
|
|
| 2010
|
Transduction of brain dopamine neurons by adenoviral vectors is modulated by car expression: Rationale for tropism modified vectors in PD gene therapy.
PLoS ONE.
5:1-9.
2010
|
|
| 2010
|
Fcy receptors are required for NF-kB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.
Molecular Neurodegeneration.
5.
2010
|
|
| 2010
|
Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.
Neurobiology of Disease.
38:434-445.
2010
|
|
| 2010
|
Target validation: The Parkinson disease perspective
2010
|
|
| 2010
|
Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivo.
Journal of Neurochemistry.
113:228-235.
2010
|
|
| 2010
|
VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.
Neurobiology of Disease.
37:330-338.
2010
|
|
| 2010
|
Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease.
Cell Death and Disease.
1.
2010
|
|
| 2009
|
O.045 Mechanisms of dystonia.
Parkinsonism and Related Disorders.
15:S12-S12.
2009
|
|
| 2009
|
Monitoring motor fluctuations in patients with parkinsons disease using wearable sensors.
IEEE Transactions on Information Technology in Biomedicine.
13:864-873.
2009
|
|
| 2009
|
Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration.
PLoS ONE.
4.
2009
|
|
| 2009
|
Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: Role of endogenous acetylcholine
2009
|
|
| 2009
|
Targets for neuroprotection in Parkinson's disease
2009
|
|
| 2009
|
Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia.
Neurobiology of Disease.
34:133-145.
2009
|
|
| 2009
|
Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy
2009
|
|
| 2009
|
Racial differences in parkinson's disease medication use in the reasons for geographic and racial differences in stroke cohort: A cross-sectional study.
Neuroepidemiology.
33:329-334.
2009
|
|
| 2008
|
Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking.
Current protocols in neuroscience / editorial board, Jacqueline N. Crawley ... [et al.].
2008
|
|
| 2008
|
Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of parkinson disease.
Journal of Neuropathology and Experimental Neurology.
67:1149-1158.
2008
|
|
| 2008
|
Using wearable sensors to predict the severity of symptoms and motor complications in late stage Parkinson's Disease..
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.
3686-3689.
2008
|
|
| 2008
|
Striatal histone modifications in models of levodopa-induced dyskinesia.
Journal of Neurochemistry.
106:486-494.
2008
|
|
| 2008
|
Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism.
European Journal of Neuroscience.
27:1647-1658.
2008
|
|
| 2008
|
The pathophysiological basis of dystonias.
Nature Reviews Neuroscience.
9:222-234.
2008
|
|
| 2008
|
Transcriptional dysregulation in a transgenic model of Parkinson disease.
Neurobiology of Disease.
29:515-528.
2008
|
|
| 2008
|
Design of clinical trials of gene therapy in Parkinson disease.
Experimental Neurology.
209:41-47.
2008
|
|
| 2008
|
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity..
Molecular Brain.
1:17.
2008
|
|
| 2008
|
Processing wearable sensor data to optimize deep-brain stimulation.
IEEE Pervasive Computing.
7:56-61.
2008
|
|
| 2007
|
Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro.
Biochemical and Biophysical Research Communications.
363:846-851.
2007
|
|
| 2007
|
Dopamine release is impaired in a mouse model of DYT1 dystonia.
Journal of Neurochemistry.
102:783-788.
2007
|
|
| 2007
|
Pharmacological inhibition of PARP-1 reduces α-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models.
Biochemical and Biophysical Research Communications.
357:596-602.
2007
|
|
| 2007
|
Effects of gender on nigral gene expression and parkinson disease.
Neurobiology of Disease.
26:606-614.
2007
|
|
| 2007
|
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
Journal of Neurochemistry.
100:1449-1457.
2007
|
|
| 2007
|
Molecular markers of early Parkinson's disease based on gene expression in blood
2007
|
|
| 2006
|
Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia.
Neurobiology of Disease.
24:318-325.
2006
|
|
| 2006
|
No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain.
Acta Neuropathologica.
112:439-449.
2006
|
|
| 2006
|
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking
2006
|
|
| 2006
|
Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.
European Journal of Neuroscience.
23:3171-3175.
2006
|
|
| 2005
|
Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia.
Journal of Neural Transmission.
112:1613-1624.
2005
|
|
| 2005
|
Alpha-synuclein and chaperones in dementia with Lewy bodies.
Journal of Neuropathology and Experimental Neurology.
64:1058-1066.
2005
|
|
| 2005
|
Somatic mitochondrial DNA mutations in single neurons and glia.
Neurobiology of Aging.
26:1343-1355.
2005
|
|
| 2005
|
Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation
2005
|
|
| 2005
|
Applications of laser capture microdissection in the study of neurodegenerative disease.
Archives of Neurology.
62:203-205.
2005
|
|
| 2005
|
Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: Neuronal selectivity and potential neuroprotective role of HAP1.
Human Molecular Genetics.
14:179-189.
2005
|
|
| 2005
|
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Neuropharmacology.
48:503-516.
2005
|
|
| 2005
|
Pacemaker-induced tachycardia caused by inappropriate response to parkinsonian tremor.
Neurology.
65:1676-1677.
2005
|
|
| 2004
|
Levodopa and the progression of parkinson’s disease.
New England Journal of Medicine.
351:2498-2508.
2004
|
|
| 2004
|
Data mining techniques to detect motor fluctuations in Parkinson's disease.
Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings.
26 VII:4766-4769.
2004
|
|
| 2004
|
NMDA-R1 antisense oligodeoxynucleotides modify formalin-induced nociception and spinal c-Fos expression in rat spinal cord
2004
|
|
| 2004
|
L-type Ca2+ channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment
2004
|
|
| 2004
|
Neuroprotective strategies for Parkinson's disease.
Current Neuropharmacology.
2:309-322.
2004
|
|
| 2004
|
Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
Pharmacology and Therapeutics.
102:155-174.
2004
|
|
| 2004
|
Changes in the expression of the NR2B subunit during aging in macaque monkeys.
Neurobiology of Aging.
25:201-208.
2004
|
|
| 2004
|
Dopamine D1-Dependent Trafficking of Striatal N-Methyl-D-aspartate Glutamate Receptors Requires Fyn Protein Tyrosine Kinase but Not DARPP-32.
Molecular Pharmacology.
65:121-129.
2004
|
|
| 2004
|
Dopamine transmission in DYT1 dystonia.
2004
|
|
| 2003
|
Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease..
Neurology.
61:S30-S31.
2003
|
|
| 2003
|
II: A2A receptor modulation for symptomatic therapy in Parkinson's disease: Adenosine A2A receptor modulation of motor systems in PD.
Neurology.
61.
2003
|
|
| 2003
|
Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain.
Brain Research.
986:12-21.
2003
|
|
| 2003
|
Lighting up the senses: FM1-43 loading of sensory cells through nonselective ion channels
2003
|
|
| 2003
|
Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: Analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.
Neurobiology of Disease.
14:624-636.
2003
|
|
| 2003
|
Predicting the Potential of Wearable Technology
2003
|
|
| 2003
|
Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum.
Journal of Neurochemistry.
85:935-943.
2003
|
|
| 2003
|
TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion.
Neurobiology of Disease.
12:11-24.
2003
|
|
| 2003
|
Wearable technology's applications in Parkinson's disease.
2003
|
|
| 2002
|
Identification of nitric oxide synthase neurons for laser capture microdissection and mRNA quantification
2002
|
|
| 2002
|
Dopamine transmission in DYT1 dystonia: A biochemical and autoradiographical study.
Neurology.
59:445-448.
2002
|
|
| 2002
|
Tyrosine phosphorylation of the metabotropic glutamate receptor mGluR5 in striatal neurons.
Neuropharmacology.
43:161-173.
2002
|
|
| 2002
|
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Science.
296:2238-2243.
2002
|
|
| 2002
|
Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat.
Brain Research.
101:132-135.
2002
|
|
| 2002
|
Expression and activity of antioxidants in the brain in progressive supranuclear palsy.
Brain Research.
930:170-181.
2002
|
|
| 2002
|
Inherited movement disorders.
Neurologic Clinics.
20:759-778.
2002
|
|
| 2001
|
Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane
2001
|
|
| 2001
|
Dystonia and its disorders.
Neurologic Clinics.
19:681-705.
2001
|
|
| 2001
|
Gene expression profiling in the post-mortem human brain - No cause for dismay.
Journal of Chemical Neuroanatomy.
22:79-94.
2001
|
|
| 2000
|
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
2000
|
|
| 2000
|
alpha-actinin-2 in rat striatum: localization and interaction with NMDA glutamate receptor subunits..
Brain Research.
79:77-87.
2000
|
|
| 2000
|
α-Actinin-2 in rat striatum: Localization and interaction with NMDA glutamate receptor subunits.
Brain Research.
79:77-87.
2000
|
|
| 2000
|
Localization of dopaminergic markers in the human subthalamic nucleus.
Journal of Comparative Neurology.
421:247-255.
2000
|
|
| 2000
|
Localization of dopaminergic markers in the human subthalamic nucleus.
Journal of Comparative Neurology.
421:247-255.
2000
|
|
| 2000
|
Research goals in progressive supranuclear palsy.
Movement Disorders.
15:446-458.
2000
|
|
| 2000
|
Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum.
Journal of Comparative Neurology.
419:407-421.
2000
|
|
| 2000
|
Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors.
Neuroscience.
97:195-204.
2000
|
|
| 2000
|
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Molecular Pharmacology.
57:342-352.
2000
|
|
| 2000
|
Frontal lobe dysfunction in progressive supranuclear palsy: Evidence for oxidative stress and mitochondrial impairment.
Journal of Neurochemistry.
74:878-881.
2000
|
|
| 2000
|
Research goals in progressive supranuclear palsy.
Movement Disorders.
15:446-458.
2000
|
|
| 1999
|
Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons.
Journal of Comparative Neurology.
415:204-217.
1999
|
|
| 1999
|
Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons.
Journal of Comparative Neurology.
415:204-217.
1999
|
|
| 1999
|
Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia.
Journal of Comparative Neurology.
415:266-284.
1999
|
|
| 1999
|
Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia.
Journal of Comparative Neurology.
415:266-284.
1999
|
|
| 1999
|
Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain.
Annals of Neurology.
46:761-769.
1999
|
|
| 1999
|
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
1999
|
|
| 1999
|
Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain.
Annals of Neurology.
46:761-769.
1999
|
|
| 1999
|
Association of AMPA receptors with a subset of glutamate receptor- interacting protein in vivo
1999
|
|
| 1999
|
Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.
Journal of Neurochemistry.
73:881-884.
1999
|
|
| 1999
|
Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia.
Journal of Comparative Neurology.
407:33-46.
1999
|
|
| 1999
|
Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia.
Journal of Comparative Neurology.
407:33-46.
1999
|
|
| 1999
|
Immunohistochemical localization of N-methyl-D-aspartate and α-amino- 3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat.
Neuroscience.
89:209-220.
1999
|
|
| 1999
|
Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat.
Brain Research.
64:11-23.
1999
|
|
| 1999
|
Distribution of group III mGluRs in rat basal ganglia with subtype-specific antibodies.
Annals of the New York Academy of Sciences.
868:531-534.
1999
|
|
| 1999
|
NMDA receptors and nitric oxide synthase.
Molecular Psychiatry.
4:13-14.
1999
|
|
| 1999
|
Neuroprotective therapies.
Medical Clinics of North America.
83:509-523.
1999
|
|
| 1998
|
Simultaneous isotopic and nonisotopic in situ hybridization histochemistry with cRNA probes.
Brain Research.
3:22-32.
1998
|
|
| 1998
|
Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat.
Neuroscience.
86:783-798.
1998
|
|
| 1998
|
Expression of the early onset torsion dystonia gene (DYT1) in human brain.
Annals of Neurology.
43:669-673.
1998
|
|
| 1998
|
Differential localization of the mRNAs for the pertussis toxin insensitive G-protein alpha sub-units G(q), G11, and G(z) in the rat brain, and regulation of their expression after striatal deafferentation.
Brain Research.
54:298-310.
1998
|
|
| 1998
|
NMDAR1 glutamate receptor subunit isoforms in neostriatal, neocortical, and hippocampal nitric oxide synthase neurons
1998
|
|
| 1998
|
Expression of N-Methyl-D-Aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons.
Journal of Comparative Neurology.
390:91-101.
1998
|
|
| 1998
|
Expression of N-Methyl-D-Aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus.
Journal of Comparative Neurology.
390:63-74.
1998
|
|
| 1998
|
Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons.
Journal of Comparative Neurology.
390:91-101.
1998
|
|
| 1998
|
Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Hippocampus and cortex.
Journal of Comparative Neurology.
390:75-90.
1998
|
|
| 1998
|
Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus.
Journal of Comparative Neurology.
390:63-74.
1998
|
|
| 1998
|
Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia.
Journal of Comparative Neurology.
390:5-19.
1998
|
|
| 1998
|
Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia.
Journal of Comparative Neurology.
390:5-19.
1998
|
|
| 1998
|
The human N-methyl-D-aspartate receptor 2C subunit: Genomic analysis, distribution in human brain, and functional expression.
Journal of Neurochemistry.
71:1953-1968.
1998
|
|
| 1998
|
Treating Parkinson's disease.
1998
|
|
| 1997
|
N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo.
Neuroscience Letters.
236:91-94.
1997
|
|
| 1997
|
Differential expression of kainate receptors in the basal ganglia of the developing and adult rat brain.
Brain Research.
768:215-223.
1997
|
|
| 1997
|
Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus.
Brain Research.
48:259-269.
1997
|
|
| 1997
|
Cloning and stable expression of the mGluR1b subtype of human metabotropic receptors and pharmacological comparison with the mGluR5a subtype.
Neuropharmacology.
36:917-931.
1997
|
|
| 1997
|
Erratum: Malondialdehyde immunohistochemistry in Parkinson's disease (Movement Disorders (1996) 11 (592)).
Movement Disorders.
12:131.
1997
|
|
| 1997
|
Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellum.
Neurobiology of Disease.
4:35-46.
1997
|
|
| 1997
|
Huntingtin immunoreactivity in the rat neostriatum: Differential accumulation in projection and interneurons.
Experimental Neurology.
144:239-247.
1997
|
|
| 1996
|
Immunohistochemical localization of metabotropic glutamate receptors (mGluRs) in the rat basal ganglia.
Neuropharmacology.
35:A30-A30.
1996
|
|
| 1996
|
Metabotropic glutamate receptors modulate striatal quinolinic acid toxicity.
Neuropharmacology.
35:A22-A22.
1996
|
|
| 1996
|
Expression of N-methyl-D-aspartate glutamate receptor subunits in the prefrontal cortex of the rat.
Neuroscience.
73:417-427.
1996
|
|
| 1996
|
Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus.
Brain Research.
42:89-102.
1996
|
|
| 1996
|
Glutamate receptor genes in Parkinson's disease.
1996
|
|
| 1996
|
Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation.
Journal of Pharmacology and Experimental Therapeutics.
276:342-352.
1996
|
|
| 1995
|
Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions.
Neuroscience Letters.
202:109-112.
1995
|
|
| 1995
|
NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum.
1995
|
|
| 1995
|
DNA fragmentation and immediate early gene expression in rat striatum following quinolinic acid administration.
Experimental Neurology.
133:207-214.
1995
|
|
| 1995
|
Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons.
Journal of Comparative Neurology.
354:241-252.
1995
|
|
| 1995
|
NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum
1995
|
|
| 1994
|
Glutamate receptor expression in rat striatum: Effect of deafferentation.
Brain Research.
647:209-219.
1994
|
|
| 1994
|
Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat.
1994
|
|
| 1994
|
Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat.
Brain Research.
21:283-292.
1994
|
|
| 1994
|
Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat
1994
|
|
| 1994
|
Metabotropic glutamate receptors are differentially regulated during development.
Neuroscience.
61:481-495.
1994
|
|
| 1994
|
Organization of N‐methyl‐D‐aspartate glutamate receptor gene expression in the basal ganglia of the rat.
Journal of Comparative Neurology.
343:1-16.
1994
|
|
| 1993
|
Alternatively spliced isoforms of the NMDAR1 glutamate receptor subunit: Differential expression in the basal ganglia of the rat.
Neuroscience Letters.
152:161-164.
1993
|
|
| 1993
|
Update on the management of Parkinson's disease.
Medical Clinics of North America.
77:169-183.
1993
|
|
| 1992
|
Magnetic Resonance Angiography in the Evaluation of Dural Carotid-Cavernous Fistulas.
Journal of Neuroimaging.
2:208-211.
1992
|
|
| 1991
|
Meningovascular syphilis with a gumma of the midbrain.
Journal of clinical neuro-ophthalmology.
11:139-143.
1991
|
|
| 1991
|
Molecular features of hypothalamic plaques in Alzheimer's disease.
American Journal of Pathology.
139:681-691.
1991
|
|
| 1988
|
Expression of the gene for preproatriopeptin in the central nervous system of the rat..
Brain Research.
464:7-13.
1988
|
|
| 1988
|
Expression of the gene for preproatriopeptin in the central nervous system of the rat.
Brain Research.
4:7-13.
1988
|
|
| 1988
|
Origin of the atriopeptin-like immunoreactive innervation of the paraventricular nucleus of the hypothalamus
1988
|
|
| 1987
|
Inhibition of the firing of vasopressin neurons by atriopeptin.
Nature.
329:151-153.
1987
|
|
| 1987
|
Ventricular atriopeptin: Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone.
Hypertension.
9:485-491.
1987
|
|
| 1986
|
Colocalization of atriopeptin-like immunoreactivity with choline acetyltransferase-and substance P-like immunoreactivity in the pedunculopontine and laterodorsal tegmental nuclei in the rat.
Brain Research.
382:163-168.
1986
|
|
| 1986
|
Opioid peptide immunoreactivity in spinal and trigeminal dorsal horn neurons projecting to the parabranchial nucleus in the rat
1986
|
|
| 1986
|
Organization of atriopeptin‐like immunoreactive neurons in the central nervous system of the rat.
Journal of Comparative Neurology.
253:315-341.
1986
|
|
| 1985
|
Atriopeptin immunoreactive neurons in cardiovascular regulatory areas of the brain in the rat.
The FASEB Journal.
44.
1985
|
|
| 1985
|
Atriopeptin-immunoreactive neurons in the brain: Presence in cardiovascular regulatory areas.
Science.
227:1047-1049.
1985
|
|
| 1985
|
Atriopeptin: potent hormone and potential neuromediator.
Trends in Neurosciences.
8:509-511.
1985
|
|
| 1985
|
Atriopeptins as cardiac hormones.
Hypertension.
7:469-482.
1985
|
|
| 1985
|
Spinal and trigeminal dorsal horn projections to the parabrachial nucleus in the rat.
Journal of Comparative Neurology.
240:153-160.
1985
|
|
| 1984
|
Proctolin in the lobster: The distribution, release, and chemical characterization of a likely neurohormone
1984
|
|
| 1977
|
Beneficial effect of fluorocarbon emulsion media on the function of neuromuscular preparations in vitro.
Journal of General Physiology.
69:655-666.
1977
|
|
